Evidence
Reviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
May 4, 2023Clinical Outcomes Webinar / Archive
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreApril 15, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreCMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Reviewing the Evidence Supporting rtCGM: Opportunities for Patient Engagement and Quality Improvement in Managed Care Pharmacy
Continuous glucose monitoring (CGM) represents a key intervention for advancing the management of diabetes and enhancing the patient experience. Importantly, pharmacy professionals remain instrumental in CGM access and related patient education efforts. Although diabetes technology has seen increased uptake over the past several years, recent innovation in real-time CGM (rtCGM) highlights an opportunity for increased patient engagement and quality improvement in managed care. During this AMCP Northwest Affiliate CE dinner meeting held on April 13, 2023, experts Nicole Ehrhardt, MD and Carly Rodriguez, PharmD, FAMCP, reviewed evidenced-based recommendations supporting the use of rtCGM in a broader population of insulin-treated patients. A panel discussion featuring regional managed care leaders explored the value of rtCGM in optimizing outcomes and reducing resource utilization among members with diabetes.
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 30, 2023Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreApril 15, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreCMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience
April 15, 2023Economic Outcomes CGM Best Practices / Interview
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreCMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
April 11, 2023Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreCMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
March 2, 2023Coverage and Benefit Design Guidelines / Policy
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CMS Expands CGM Coverage to All Patients on Insulin or Those Who Have a History of Problematic Hypoglycemia
The Centers for Medicare and Medicaid Services (CMS) expanded CGM access to beneficiaries on basal-only insulin or those with a history of level two or three hypoglycemia. Although the Local Coverage Determination (LCD) was originally anticipated to be implemented in July, CMS expanded access to CGM on April 16, 2023. This new coverage policy is aligned with consensus guidelines from the ADA and AACE, which recommend CGM for all patients on insulin at the outset of diagnosis. The new LCD, which was proposed in 2022, also removes the term “daily” as a descriptor for insulin to account for potential FDA approval of weekly insulins in the future.
Learn MoreImpact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
February 28, 2023Clinical Outcomes Coverage and Benefit Design Article / Publication
Learn MoreCGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
CGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
February 17, 2023CGM Technology and Digital Health CGM Innovations / Webinar / Archive
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CGM Innovations to Improve Diabetes Management: The Payer Value Proposition of a Next-Generation rtCGM System
Click here to download the summary from this live event or watch the webinar video archive below.
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
February 17, 2023Clinical Outcomes Article / PublicationLearn MoreJanuary 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration
January 25, 2023CGM Technology and Digital Health CGM Innovations
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
1. Psavko S et al. JMIR Hum Factors 2022;9(4):42057
Learn More
A task analysis and ease of use survey conducted among adults aged ≥65 years and certified diabetes care and education specialists (CDCESs) showed excellent useability associated with the new G7 RT-CGM system. Ease of use related to intradermal insertion and mobile app setup were assessed and compared to the fifth- and sixth-generation systems in the study, which recruited 10 older adults with no previous CGM experience and 10 CDCESs. The analysis revealed that approximately half as many tasks are needed to deploy the G7 system compared with the G6, resulting in excellent usability as assessed by older adults and CDCESs in the study, highlighted by a system usability score of 92.8. Cumulatively, these findings indicate a relatively low cognitive burden associated with the system compared with previous versions, simplifying the utilization of RT-CGM for older adults who are at higher risk for diabetes-related complications and stand to benefit from the implementation of diabetes technology. Managed care and payer decision makers may find the data presented in the study useful for informing coverage policy and criteria for RT-CGM in this vulnerable population of patients.
Psavko S, Katz N, Mirchi T, Green CR. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
